本期 13F-HR 中的全部持仓，以及相对上季度的变化。
13F 持仓，最新季度
来源SEC EDGAR13F-HR
VHCP Management III, LLC (CIK 1738053) reported $503.6M across 18 reported positions in its SEC 13F filing for 2019-12-31. Largest positions: AXSM ($160.0M, 31.77%), CNST ($118.5M, 23.54%), MIST ($33.1M, 6.57%), RLMD ($29.9M, 5.95%), ETNB ($25.2M, 5.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | AXSM | Axsome Therapeutics Inc | $160.0M | 31.77% | 1.5M | Trimmed |
| 2 | CNST | Constellation Pharmaceuticals | $118.5M | 23.54% | 2.5M | Added |
| 3 | MIST | Milestone Pharmaceuticals Inc | $33.1M | 6.57% | 2.1M | Hold |
| 4 | RLMD | Relmada Therapeutics Inc | $29.9M | 5.95% | 767,938 | New |
| 5 | ETNB | 89Bio Inc | $25.2M | 5.00% | 958,765 | New |
| 6 | TXG | 10X Genomics Inc. | $22.9M | 4.54% | 300,000 | Hold |
| 7 | FTSV | Forty Seven Inc | $20.3M | 4.04% | 516,381 | New |
| 8 | ITCI | Intra-Cellular Therapies Inc | $19.7M | 3.92% | 575,000 | New |
| 9 | ISEE | Iveric Bio Inc | $14.6M | 2.90% | 1.7M | New |
| 10 | KALV | Kalvista Pharmaceuticals | $11.0M | 2.19% | 619,905 | Trimmed |
| 11 | ADVM | Adverum Biotechnologies Inc | $10.9M | 2.16% | 946,234 | New |
| 12 | MRNS | Marinus Pharmaceuticals Inc | $10.8M | 2.15% | 5.0M | Added |
| 13 | MRSN | Mersana Therapeutics Inc | $8.9M | 1.78% | 1.6M | New |
| 14 | MYOV | Myovant Sciences Ltd | $7.1M | 1.40% | 455,255 | New |
| 15 | NXTC | Nextcure Inc | $6.7M | 1.34% | 119,693 | New |
| 16 | OBSVF | Obseva SA | $3.1M | 0.61% | 810,264 | Trimmed |
| 17 | PTGX | Protagonist Therapeutics Inc | $571,000 | 0.11% | 80,929 | Trimmed |
| 18 | BLPH | Bellerophon Therapeutics | $134,000 | 0.03% | 383,955 | Trimmed |
| 19 | BCRX | BioCryst Pharmaceuticals Inc | $0 | 0.00% | 0 | Exited |
| 20 | KA | Proteostasis Therapeutics Inc | $0 | 0.00% | 0 | Exited |
| 21 | KNSA | Kiniksa Pharmaceuticals Ltd | $0 | 0.00% | 0 | Exited |
| 22 | LJPC | La Jolla Pharmaceuticals | $0 | 0.00% | 0 | Exited |
| 23 | PRVL | Prevail Therapeutics Inc | $0 | 0.00% | 0 | Exited |
| 24 | RARX | Ra Pharmaceuticals | $0 | 0.00% | 0 | Exited |
| 25 | RDUS1 | Radius Health Inc | $0 | 0.00% | 0 | Exited |
来源：SEC 13F 申报文件 · 截至 2019-12-31